Stem cell biotech stays afloat

Embryonic stem cell biotech company linkurl:Advanced Cell Technology;http://www.advancedcell.com/ (ACT), announced today (Oct. 7) that it will be selling off $500,000 in convertible bonds in the next three months, following the company's linkurl:disclosure;http://www.the-scientist.com/blog/display/54884/ this summer that it was experiencing financial troubles. The Massachusetts-based company told linkurl:__Mass High Tech__;http://www.masshightech.com/stories/2008/10/06/daily29-Advanced-Cell-Tec

Bob Grant
Bob Grant

Bob started with The Scientist as a staff writer in 2007. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism...

View full profile.


Learn about our editorial policies.

Oct 6, 2008
Embryonic stem cell biotech company linkurl:Advanced Cell Technology;http://www.advancedcell.com/ (ACT), announced today (Oct. 7) that it will be selling off $500,000 in convertible bonds in the next three months, following the company's linkurl:disclosure;http://www.the-scientist.com/blog/display/54884/ this summer that it was experiencing financial troubles. The Massachusetts-based company told linkurl:__Mass High Tech__;http://www.masshightech.com/stories/2008/10/06/daily29-Advanced-Cell-Tech-sells-500K-in-bonds.html that it will devote money from the sale (to an Irish investment firm) towards advancing its clinical program and for general corporate use. Recently, linkurl:ACT;http://www.the-scientist.com/blog/display/54544/ has been seeking a partner to help with its preclinical programs to use embryonic stem cell therapy in treating retinal disease, blood disorders and cardiovascular disease. The company also needs funding for a program, called Myoblast, which uses adult stem cell therapy to treat heart disease. Myoblast successfully completed four Phase I clinical trials, and ACT has received clearance from the FDA to begin Phase II trials. Selling the one-year, seven percent bonds is the latest move to...
ing off $500,000 in convertible bonds in the next three months, following the company's linkurl:disclosure;http://www.the-scientist.com/blog/display/54884/ this summer that it was experiencing financial troubles. The Massachusetts-based company told linkurl:__Mass High Tech__;http://www.masshightech.com/stories/2008/10/06/daily29-Advanced-Cell-Tech-sells-500K-in-bonds.html that it will devote money from the sale (to an Irish investment firm) towards advancing its clinical program and for general corporate use. Recently, linkurl:ACT;http://www.the-scientist.com/blog/display/54544/ has been seeking a partner to help with its preclinical programs to use embryonic stem cell therapy in treating retinal disease, blood disorders and cardiovascular disease. The company also needs funding for a program, called Myoblast, which uses adult stem cell therapy to treat heart disease. Myoblast successfully completed four Phase I clinical trials, and ACT has received clearance from the FDA to begin Phase II trials. Selling the one-year, seven percent bonds is the latest move to keep the struggling company alive in the face of waning investments in yet-to-be-developed embryonic stem cell therapies. This past July, after telling the Securities and Exchange Commission that it was essentially going out of business, an ACT spokesperson told __The Scientist__ that company officials were "killing ourselves to secure funding."

Interested in reading more?

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?